Avalyn Pharma Inc. (AVLN)Healthcare | Biotechnology | Boston, United States | NasdaqGS
34.69 USD
-1.82
(-4.985%) ⇩
(Aug. 28, 2026, 4 p.m.
EDT)
After hours: 34.69 |
Hot Take ↕ | Aug. 22, 2026, 1:28 a.m. EDT
The immediate outlook is aggressively bullish driven by a powerful technical breakout. Over the last two weeks, the stock surged from roughly $30.73 to $38.37, trading significantly above both its 50-day and 200-day moving averages, which suggests strong institutional accumulation and momentum building toward the upper end of its 52-week range. Analyst sentiment reinforces this, with a 'strong buy' consensus and a mean price target of $62.25, implying substantial upside potential if clinical milestones are met. However, the long-term investment case remains neutral due to a complete lack of historical price data; without a multi-year track record to verify business durability or revenue consistency, the asset cannot be rated as a superior buy-and-hold opportunity despite its current hype. Furthermore, there is no dividend income to consider, making this purely a speculative growth play reliant on future drug approvals rather than current cash flows. |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 4.295 |
| Market Cap | 1,537,915,008 |
| Forward P/E | -18.26 |
| Website | https://www.avalynpharma.com |
| Attribute | Value |
|---|---|
| 52 Week Change | 0.17633092 |
| Address1 | 105 W First Street |
| All Time High | 40.17 |
| All Time Low | 24.15 |
| Ask | 36.58 |
| Ask Size | 1 |
| Average Analyst Rating | 1.3 - Strong Buy |
| Average Daily Volume10 Day | 156,550 |
| Average Daily Volume3 Month | 313,711 |
| Average Volume | 313,711 |
| Average Volume10Days | 156,550 |
| Bid | 36.57 |
| Bid Size | 1 |
| Book Value | 8.985 |
| City | Boston |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 34.69 |
| Current Ratio | 33.119 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,786,665,600 |
| Day High | 36.45 |
| Day Low | 34.37 |
| Debt To Equity | 4.295 |
| Display Name | Avalyn Pharma |
| Earnings Timestamp | 1,786,537,800 |
| Earnings Timestamp End | 1,794,832,200 |
| Earnings Timestamp Start | 1,794,832,200 |
| Ebitda | -109,802,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -10.952 |
| Enterprise Value | 1,202,599,040 |
| Eps Current Year | -1.94 |
| Eps Forward | -1.9 |
| Eps Trailing Twelve Months | -2.21 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 31.8452 |
| Fifty Day Average Change | 2.844799 |
| Fifty Day Average Change Percent | 0.08933212 |
| Fifty Two Week Change Percent | 17.633093 |
| Fifty Two Week High | 40.17 |
| Fifty Two Week High Change | -5.4799995 |
| Fifty Two Week High Change Percent | -0.1364202 |
| Fifty Two Week Low | 24.15 |
| Fifty Two Week Low Change | 10.539999 |
| Fifty Two Week Low Change Percent | 0.4364389 |
| Fifty Two Week Range | 24.15 - 40.17 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,777,555,800,000 |
| Float Shares | 27,409,823 |
| Forward Eps | -1.9 |
| Forward P E | -18.257895 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 55 |
| Fullday Change | -1.82 |
| Fullday Change Percent | -4.98493 |
| Fullday Price | 34.69 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.0 |
| Held Percent Institutions | 1.03254 |
| Implied Shares Outstanding | 44,333,095 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,026-04-30 |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Avalyn Pharma Inc. operates as a clinical-stage biopharmaceutical company developing inhaled medicines to treat rare respiratory diseases, including pulmonary fibrosis and other interstitial lung diseases. The company provides inhaled formulations of oral medicines directly to the lungs. Its current pipeline is focused on treating pulmonary fibrosis. Its products include AP01 and AP02, inhaled formulations of pirfenidone and nintedanib for the treatment of progressive pulmonary fibrosis and idiopathic pulmonary fibrosis; and AP03, a fixed-dose combination of inhaled pirfenidone and nintedanib to deliver dual antifibrotic mechanisms. Avalyn Pharma Inc. was formerly known as Genoa Pharmaceuticals, Inc. and changed its name to Avalyn Pharma Inc. in July 2017. The company was incorporated in 2011 and is based in Boston, Massachusetts. |
| Long Name | Avalyn Pharma Inc. |
| Market | us_market |
| Market Cap | 1,537,915,008 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_224094665 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -103,314,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 1,618,601,298 |
| Number Of Analyst Opinions | 4 |
| Open | 36.45 |
| Operating Cashflow | -97,479,000 |
| Operating Margins | 0.0 |
| Payout Ratio | 0.0 |
| Phone | (206) 707-0340 |
| Post Market Change | 0.0 |
| Post Market Change Percent | 0.0 |
| Post Market Price | 34.69 |
| Post Market Time | 1,787,959,806 |
| Previous Close | 36.51 |
| Price Eps Current Year | -17.881441 |
| Price Hint | 2 |
| Price To Book | 3.8608792 |
| Profit Margins | 0.0 |
| Quick Ratio | 32.76 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.25 |
| Region | US |
| Regular Market Change | -1.82 |
| Regular Market Change Percent | -4.98493 |
| Regular Market Day High | 36.45 |
| Regular Market Day Low | 34.37 |
| Regular Market Day Range | 34.37 - 36.45 |
| Regular Market Open | 36.45 |
| Regular Market Previous Close | 36.51 |
| Regular Market Price | 34.69 |
| Regular Market Time | 1,787,947,201 |
| Regular Market Volume | 202,893 |
| Sand P52 Week Change | 0.20204377 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 44,333,095 |
| Shares Percent Shares Out | 0.0468 |
| Shares Short | 2,072,596 |
| Shares Short Previous Month Date | 1,784,073,600 |
| Shares Short Prior Month | 2,190,330 |
| Short Name | Avalyn Pharma Inc. |
| Short Percent Of Float | 0.0468 |
| Short Ratio | 10.01 |
| Source Interval | 15 |
| State | MA |
| Symbol | AVLN |
| Target High Price | 80.0 |
| Target Low Price | 52.0 |
| Target Mean Price | 62.25 |
| Target Median Price | 58.5 |
| Total Cash | 352,424,992 |
| Total Cash Per Share | 7.949 |
| Total Debt | 17,109,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -2.21 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 30.403572 |
| Two Hundred Day Average Change | 4.2864265 |
| Two Hundred Day Average Change Percent | 0.14098431 |
| Type Disp | Equity |
| Volume | 202,893 |
| Website | https://www.avalynpharma.com |
| Zip | 2,127 |